(Q44446994)

3 December 2017

title

Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan (English)

1 reference

3 December 2017

1 reference

Ching-Tien Peng

1

1 reference

3 December 2017

Kuan-Chih Chow

2

1 reference

3 December 2017

Jeon-Hor Chen

3

1 reference

3 December 2017

Yi-Ping Chiang

4

1 reference

3 December 2017

Tze-Yi Lin

5

1 reference

3 December 2017

Chang-Hai Tsai

6

1 reference

3 December 2017

publication date

1 June 2003

1 reference

European Journal of Haematology

3 December 2017

published in

1 reference

3 December 2017

volume

70

1 reference

3 December 2017

issue

6

1 reference

3 December 2017

page(s)

392-397

1 reference

Hepatic iron concentration: noninvasive estimation by means of MR imaging techniques

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00071.X

Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00071.X

7 January 2021

Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00071.X

7 January 2021

1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00071.X

7 January 2021

The toxic effects of desferrioxamine

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00071.X

7 January 2021

Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00071.X

7 January 2021

Heart transplantation in a case of juvenile hereditary haemochromatosis followed up by MRI and endomyocardial biopsies

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00071.X

7 January 2021

Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00071.X

7 January 2021

Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00071.X

7 January 2021

Efficacy and safety of oral iron chelator L1 in anaemic rheumatoid arthritis patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00071.X

7 January 2021

Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00071.X

7 January 2021

Sustained normalization of cardiac function by chelation therapy in thalassaemia major

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00071.X

7 January 2021

Trace metal methods for nutritional studies

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00071.X

7 January 2021

Survival in medically treated patients with homozygous beta-thalassemia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00071.X

7 January 2021

Long-term trial with the oral iron chelator 1, 2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00071.X

7 January 2021

L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00071.X

7 January 2021

Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00071.X

7 January 2021

Results of long‐term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00071.X

7 January 2021

Iron-chelation therapy with oral deferiprone in patients with thalassemia major

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00071.X

7 January 2021

Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00071.X

7 January 2021

Combined therapy with deferiprone and desferrioxamine

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00071.X

7 January 2021

Assessment of tissue iron overload by nuclear magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00071.X

7 January 2021

Myocardial iron deposition in beta-thalassemia studied by magnetic resonance imaging.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00071.X

7 January 2021

Qualitative and quantitative magnetic resonance imaging in haemoglobin H disease: screening for iron overload

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00071.X

7 January 2021

Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00071.X

7 January 2021

Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00071.X

7 January 2021

10.1034/J.1600-0609.2003.00071.X

Identifiers

DOI

1 reference

3 December 2017

1 reference